PEGYLATED INTERFERON +/- RIBAVIRIN FOR CHILDREN WITH HCV

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者的研究机构。 这是一项为期五年的研究，旨在评估6-18岁儿童使用聚乙二醇干扰素联合或不联合利巴韦林治疗丙型肝炎的效果。还通过辅助研究监测副作用、对生长、体重和心理状况以及生活方式变化的影响。该研究由NIH资助，部分由Roche Pharmacueticals资助。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a five year study to assess the effect of treatment of Hepatitis C with pegylated interferon with or without ribavirin in children between ages 6-18. The side effects , effects on growth, weight and psychological profile and life style changes are also monitored through ancillary studies. The study is funded by the NIH and in part by Roche Pharmacueticals.